386 results on '"Filipits, M."'
Search Results
2. A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
3. Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer
4. ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors
5. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
6. 123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE)
7. P270 Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
8. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype
9. Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer
10. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
11. Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
12. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses
13. Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras–Raf–MEK–ERK pathway
14. Adjuvant therapy in non-small cell lung cancer: Current status and future perspectives
15. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
16. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement†
17. Der prognostische Wert der p53-Immunhistochemie beim Gallenblasenkarzinom
18. Drug resistance factors in acute myeloid leukemia: a comparative analysis
19. Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
20. P06.08 Immunomodulatory biomarkers in neoadjuvant chemotherapy of breast cancer
21. Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status
22. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
23. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis
24. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy: 742
25. The Prognostic Value of p53 Immunohistochemistry in Gallbladder Carcinoma
26. Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2-positive early breast cancer: A TransHERA study
27. Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
28. Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
29. Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
30. Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials
31. Abstract P2-08-04: Prediction of distant recurrence by EndoPredict in patients with estrogen receptor-positive, HER2-negative breast cancer who received adjuvant endocrine therapy plus chemotherapy (ET+C) or endocrine therapy alone (ET)
32. Abstract P1-17-05: The impact of clinical risk assessment versus PAM-50 ROR score on prognosis and therapeutic decision making in patients with hormone-receptor positive early stage breast cancer
33. Abstract P4-08-05: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years
34. Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?
35. PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER1/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
36. 59PHEALTH ECONOMIC ANALYSIS OF GUIDELINE AND GENE EXPRESSION SIGNATURE-BASED RISK STRATIFICATION OF DISTANT RECURRENCE IN EARLY BREAST CANCER PATIENTS
37. ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors
38. mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohort
39. Abstract GS6-04: The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34
40. Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
41. P2.09-004 PD-L1 Protein Expression Is Negative Prognostic Factor in Malignant Pleural Mesothelioma in Central Europe
42. P2.03-025 Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib
43. Expression of ARs in triple negative breast cancer tumors: A potential prognostic factor?
44. Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer
45. 495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
46. 458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
47. 1417P - Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
48. Abstract P2-08-21: Stromal co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer
49. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
50. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.